within Pharmacolibrary.Drugs.J_AntiinfectivesForSystemicUse.J05A_DirectActingAntivirals.J05AR03_TenofovirDisoproxilAndEmtricitabine;

model TenofovirDisoproxilAndEmtricitabine
  extends Pharmacolibrary.Drugs.ATC.J.J05AR03;

  annotation (Documentation(
info       = "<html><body><table><tr><td>Drug:</td><td>J05AR03</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Tenofovir disoproxil and emtricitabine is a fixed-dose combination antiretroviral medication used for the treatment and prevention (pre-exposure prophylaxis, PrEP) of HIV-1 infection in adults and adolescents. Both drugs are reverse transcriptase inhibitors: tenofovir is a nucleotide analog, and emtricitabine is a nucleoside analog. The combination is currently approved and widely used in clinical practice.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetics reported in healthy adult volunteers, steady-state, after oral administration under fasting conditions.</p><h4>References</h4><ol><li><p>Dando, TM, &amp; Wagstaff, AJ (2004). Emtricitabine/tenofovir disoproxil fumarate. <i>Drugs</i> 64(18) 2075–2084. DOI:<a href=\"https://doi.org/10.2165/00003495-200464180-00005\">10.2165/00003495-200464180-00005</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/15341498/\">https://pubmed.ncbi.nlm.nih.gov/15341498</a></p></li><li><p>McGowan, IM, et al., &amp; Cranston, RD (2022). An Open-Label Pharmacokinetic and Pharmacodynamic Assessment of Tenofovir Gel and Oral Emtricitabine/Tenofovir Disoproxil Fumarate. <i>AIDS research and human retroviruses</i> 38(4) 279–287. DOI:<a href=\"https://doi.org/10.1089/AID.2021.0115\">10.1089/AID.2021.0115</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/34541872/\">https://pubmed.ncbi.nlm.nih.gov/34541872</a></p></li><li><p>Thurman, AR, et al., &amp; Doncel, GF (2021). Safety and Pharmacokinetics of a Tenofovir Alafenamide Fumarate-Emtricitabine based Oral Antiretroviral Regimen for Prevention of HIV Acquisition in Women: A Randomized Controlled Trial. <i>EClinicalMedicine</i> 36 100893–None. DOI:<a href=\"https://doi.org/10.1016/j.eclinm.2021.100893\">10.1016/j.eclinm.2021.100893</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/34041459/\">https://pubmed.ncbi.nlm.nih.gov/34041459</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
end TenofovirDisoproxilAndEmtricitabine;
